Key result
Immunization with the TRASP chimeric protein adjuvanted with Poly-ICLC induced robust protective immunity, resulting in a 96.7% reduction in parasitemia and 100% survival in mice, and significantly reduced tissue parasitism in dogs.
Why the study?
Immunization with ASP-2 and TS antigens confers protection against Trypanosoma cruzi, prompting evaluation of a chimeric protein containing immunogenic regions of both antigens compared with a standard heterologous prime-boost protocol.
Does TRASP associated with Poly-ICLC prevent Trypanosoma cruzi infection in experimental models?
Does TRASP associated with Poly-ICLC prevent Trypanosoma cruzi infection in experimental models?
Answers are grounded in this paper and cite their sources.
A novel chimeric protein vaccine (TRASP) adjuvanted with Poly-ICLC provides robust protection against T. cruzi infection in mice and dogs, offering a potentially safer and more scalable alternative to viral vector vaccines for Chagas' disease.
Immunization with the Amastigote Surface Protein-2 (ASP-2) and Trans -sialidase (TS) antigens either in the form of recombinant protein, encoded in plasmids or human adenovirus 5 (hAd5) confers robust protection against various lineages of Trypanosoma cruzi . Herein we generated a chimeric protein containing the most immunogenic regions for T and B cells from TS and ASP-2 (TRASP) and evaluated its immunogenicity in comparison with our standard protocol of heterologous prime-boost using plasmids and hAd5. Mice immunized with TRASP protein associated to Poly-ICLC (Hiltonol) were highly resistant to challenge with T. cruzi , showing a large decrease in tissue parasitism, parasitemia and no lethality. This protection lasted for at least 3 months after the last boost of immunization, being equivalent to the protection induced by DNA/hAd5 protocol. TRASP induced high levels of T. cruzi- specific antibodies and IFNγ-producing T cells and protection was primarily mediated by CD8 + T cells and IFN-γ. We also evaluated the toxicity, immunogenicity, and efficacy of TRASP and DNA/hAd5 formulations in dogs. Mild collateral effects were detected at the site of vaccine inoculation. While the chimeric protein associated with Poly-ICLC induced high levels of antibodies and CD4 + T cell responses, the DNA/hAd5 induced no antibodies, but a strong CD8 + T cell response. Immunization with either vaccine protected dogs against challenge with T. cruzi . Despite the similar efficacy, we conclude that moving ahead with TRASP together with Hiltonol is advantageous over the DNA/hAd5 vaccine due to pre-existing immunity to the adenovirus vector, as well as the cost-benefit for development and large-scale production.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2023) studied Chagas' disease (Trypanosoma cruzi infection) (n=36). TRASP (ASP-2/Trans-sialidase chimeric protein) with Poly-ICLC adjuvant vs. PBS, adjuvant alone, or DNA/hAd5 vaccine was evaluated on Survival rate in mice after T. cruzi challenge (p=<0.05). Immunization with the TRASP chimeric protein adjuvanted with Poly-ICLC induced robust protective immunity, resulting in a 96.7% reduction in parasitemia and 100% survival in mice, and significantly reduced tissue parasitism in dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: